Publication:
Radioimmune Imaging of α4β7 Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease

Simple item page
dc.affiliation.dptoUC3M. Departamento de Bioingenieríaes
dc.affiliation.grupoinvUC3M. Grupo de Investigación: Biomedical Imaging and Instrumentation Groupes
dc.contributor.authorSignore, Alberto
dc.contributor.authorBonfiglio, Rita
dc.contributor.authorVarani, Michela
dc.contributor.authorGalli, Filippo
dc.contributor.authorCampagna, Giuseppe
dc.contributor.authorDesco Menéndez, Manuel
dc.contributor.authorCusso Mula, Lorena
dc.contributor.authorMattei, Maurizio
dc.contributor.authorWunder, Andreas
dc.contributor.authorBorri, Filippo
dc.contributor.authorLupo, Maria T.
dc.contributor.authorBonanno, Elena
dc.contributor.funderComunidad de Madrides
dc.contributor.funderInstituto de Salud Carlos III (España)es
dc.date.accessioned2023-11-16T10:42:59Z
dc.date.available2023-11-16T10:42:59Z
dc.date.issued2023-03-01
dc.description.abstractImaging using radiolabelled monoclonal antibodies can provide, non-invasively, molecular information which allows for the planning of the best treatment and for monitoring the therapeutic response in cancer, as well as in chronic inflammatory diseases. In the present study, our main goal was to evaluate if a pre-therapy scan with radiolabelled anti-α4β7 integrin or radiolabelled anti-TNFα mAb could predict therapeutic outcome with unlabelled anti-α4β7 integrin or anti-TNFα mAb. To this aim, we developed two radiopharmaceuticals to study the expression of therapeutic targets for inflammatory bowel diseases (IBD), to be used for therapy decision making. Both anti-α4β7 integrin and anti-TNFα mAbs were successfully radiolabelled with technetium-99m with high labelling efficiency and stability. Dextran sulfate sodium (DSS)-induced colitis was used as a model for murine IBD and the bowel uptake of radiolabelled mAbs was evaluated ex vivo and in vivo by planar and SPECT/CT images. These studies allowed us to define best imaging strategy and to validate the specificity of mAb binding in vivo to their targets. Bowel uptake in four different regions was compared to immunohistochemistry (IHC) score (partial and global). Then, to evaluate the biomarker expression prior to therapy administration, in initial IBD, another group of DSS-treated mice was injected with radiolabelled mAb on day 2 of DSS administration (to quantify the presence of the target in the bowel) and then injected with a single therapeutic dose of unlabelled anti-α4β7 integrin or anti-TNFα mAb. Good correlation was demonstrated between bowel uptake of radiolabelled mAb and immunohistochemistry (IHC) score, both in vivo and ex vivo. Mice treated with unlabelled α4β7 integrin and anti-TNFα showed an inverse correlation between the bowel uptake of radiolabelled mAb and the histological score after therapy, proving that only mice with high α4β7 integrin or TNFα expression will benefit of therapy with unlabelled mAb.en
dc.description.sponsorshipThis work has been supported by grants of Boehringer Ingelheim Pharma GmbH, & Co. KG, Biberach an der Riß, Germany. This work was partially supported by Instituto de Salud Carlos III (grant PT20/00044), co-funded by European Regional Development Fund (ERDF), “A way to make Europe” and by Comunidad de Madrid (S2022/BMD-7403 RENIM-CM), co-funded by European Structural and Investment Fund. And by the Fundación Ramón Areces.en
dc.format.extent15es
dc.identifier.bibliographicCitationSignore, A., Bonfiglio, R., Varani, M., Galli, F., Campagna, G., Desco, M., Cussó, L., Mattei, M., Wunder, A., Borri, F., Lupo, M. T., & Bonanno, E. (2023). Radioimmune imaging of α4β7 integrin and TNFα for diagnostic and therapeutic applications in inflammatory bowel disease. Pharmaceutics, 15(3), 817.en
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics15030817
dc.identifier.issn1999-4923
dc.identifier.publicationfirstpage1es
dc.identifier.publicationissue3es
dc.identifier.publicationlastpage15es
dc.identifier.publicationtitlePharmaceuticsen
dc.identifier.publicationvolume15es
dc.identifier.urihttps://hdl.handle.net/10016/38886
dc.identifier.uxxiAR/0000033464
dc.language.isoengen
dc.publisherMDPIen
dc.relation.projectIDComunidad de Madrid. S2022/BMD-7403/RENIM-CMes
dc.relation.projectIDInstituto de Salud Carlos III. PT20/00044es
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.rightsThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) licenseen
dc.rightsAtribución 3.0 España*
dc.rights.accessRightsopen accessen
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject.ecienciaBiología y Biomedicinaes
dc.subject.ecienciaFarmaciaes
dc.subject.ecienciaMedicinaes
dc.subject.otherInflammatory bowel diseaseen
dc.subject.otherDSS-mouse modelen
dc.subject.otherTNFαen
dc.subject.otherα4β7 integrinen
dc.subject.otherImaging inflammationen
dc.titleRadioimmune Imaging of α4β7 Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Diseaseen
dc.typeresearch article*
dc.type.hasVersionVoR*
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
radioimmune_PHARMACEUTICS_2023.pdf
Size:
2.72 MB
Format:
Adobe Portable Document Format
Download
Collections
DBIAB - BIIG - Journal Articles